AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas

Patient organisation comments

A representative from British Skin Foundation gave the following comments.

AMBLor is a new technology that has the potential to benefit patients and healthcare providers. It could assist with determining appropriate treatment paths for people with melanoma. AMBLor offers a notable change in prognostic tests for melanoma. It may lessen the worries of patients and could save the health service time and resources that can be used elsewhere.

Communication and advice on new technologies like AMBLor are important to raise awareness among healthcare providers and the public. Without this, there may be unequal access to novel technologies in different locations.